NRX Pharmaceuticals (NRXP) Retained Earnings (2017 - 2026)
NRX Pharmaceuticals (NRXP) posted quarterly Retained Earnings of $294.5 million for Q1 2026, up 13.87% year-over-year from $258.6 million in Q1 2025, and up 195.95% quarter-over-quarter from -$306.9 million in Q4 2025.
NRX Pharmaceuticals (NRXP) Retained Earnings (2017 - 2026) Analysis & Trends
NRX Pharmaceuticals (NRXP) has reported Retained Earnings for 10 consecutive years, with $294.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Retained Earnings rose 13.87% year-over-year to $294.5 million; the TTM figure through Mar 2026 stood at $294.5 million (up 13.87% YoY), while the FY2025 annual figure was -$306.9 million, down 10.29% from the prior year.
- Retained Earnings grew to $294.5 million in Q1 2026 per NRXP's latest filing, from -$306.9 million in the prior quarter.
- Across five years, Retained Earnings topped out at $294.5 million in Q1 2026 and bottomed at -$307.3 million in Q3 2025.
- Historically, Retained Earnings has averaged -$56.2 million across 5 years, with a median of -$22000.0 in 2023.
- Annual changes were most pronounced in 2024 — Retained Earnings slumped 1223513.64% — and 2025, when it soared 8620333.33%.
- NRX Pharmaceuticals' Retained Earnings stood at $230.3 million in 2022, then plunged by 209.9% to -$253.1 million in 2023, then slipped by 9.93% to -$278.3 million in 2024, then retreated by 10.29% to -$306.9 million in 2025, then surged by 195.95% to $294.5 million in 2026.
- Business Quant data shows NRXP's Retained Earnings at $294.5 million in Q1 2026, -$306.9 million in Q4 2025, and -$307.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -6.33 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 20.91 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.57 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 4.38 Bn |
| 10 | NRX Pharmaceuticals | 132.53 Mn | 105.83 Mn | 426,000.00 | -324.85 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 294.48 Mn |
| Dec 31, 2025 | -306.90 Mn |
| Sep 30, 2025 | -307.26 Mn |
| Jun 30, 2025 | -301.37 Mn |
| Mar 31, 2025 | 258.61 Mn |
| Dec 31, 2024 | -278.27 Mn |
| Sep 30, 2024 | -269.20 Mn |
| Jun 30, 2024 | -267.57 Mn |
| Mar 31, 2024 | -3,000.00 |
| Dec 31, 2023 | -253.15 Mn |
| Sep 30, 2023 | -22,000.00 |
| Jun 30, 2023 | -22,000.00 |
| Mar 31, 2023 | 106,000.00 |
| Dec 31, 2022 | 230.34 Mn |
| Sep 30, 2022 | -212.76 Mn |
| Jun 30, 2022 | 228.96 Mn |
| Mar 31, 2022 | 228.31 Mn |
| Dec 31, 2021 | 203.99 Mn |
| Sep 30, 2021 | 161.26 Mn |
| Jun 30, 2021 | -115.79 Mn |